To compare the efficiency of treatment between different types of physicians, researchers plan to enroll roughly 600 Washington D.C. clinic patients with hepatitis C infections or hepatitis C and HIV co-infections in the trial.
Of the enrollees, about 350 participants will continue treatment with their current specialist, and 250 participants will be assigned to a primary care physician, physician assistant or nurse practitioner for treatment.
Both groups of patients will receive the same doses of hepatitis C virus treatment for two to six months, and all participants will be monitored over a 10-year period for short-term and long-term treatment outcomes.
In addition to determining whether healthcare provider type influences outcomes, the researchers will also study the safety of the drug, how well it is tolerated and whether there are differences in outcomes for people infected with both hepatitis C and HIV compared with those with hepatitis C alone.
More articles on hepatitis C care:
Hep C transmission during routine surgeries highlights need for tight infection control
Door-to-door campaign in Philadelphia screens, treats hepatitis C patients
Risk-based strategy relying on EMRs may miss 80 percent of hepatitis C patients
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
